975 Cornforth Drive
Kent Science Park
Sittingbourne, Kent ME9 8PX
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
Kent Science Park
Sittingbourne, Kent ME9 8PX
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
National Heart & Lung Institute
Sir Alexander Fleming Building
Imperial College, London SW7 2AZ
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
Sir Alexander Fleming Building
Imperial College, London SW7 2AZ
T 01795 437426
F 01795 423440
E info@irpharma.co.uk
Model systems
Asthma
The IR Pharma evaluation process systematically provides models delivering endpoint measurements for:
- Acute and Chronic models of allergic asthma
- Inflammation
- Experimental and therapeutic dose ranging
- Lung function: invasive and non-invasive - EAR, LAR and AHR
- Histopathology
- Non-invasive biomarkers (exhaled indicators)
Chronic Obstructive Pulmonary Disease (COPD)
- Acute and chronic models of smoke induced airway inflammation in 3 different species.
- Steroid sensitive and resistant models of COPD (inflammation and emphysema)
Models are available delivering endpoint measurements for:
- Lung Function
- Inflammation
- Histopathology
- Imaging
- Isolated Tissue Bio-Assay
Cough
In line with increased demand for means of evaluating both new treatments aimed at cough relief and to provide sensitive methods for detecting unwanted induction of cough by new drugs, IR Pharma has developed a range of tests and models based on both human and animal tissue samples, designed to investigate cough potentiation and treatment. They include:
- a unique human vagus nerve model that allows proof of concept profiling in human tissue
- Induced cough models (to a range of exogenous and endogenous tussive agents)
- Induced exacerbated cough (for example post smoke exposure)